Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases

被引：67

作者：

Alagha, Khuder ^{[1
]}

Palot, Alain ^{[1
]}

Sofalvi, Tunde ^{[1
]}

Pahus, Laurie ^{[1
]}

Gouitaa, Marion ^{[1
]}

Tummino, Celine ^{[1
]}

Martinez, Stephanie ^{[1
]}

Charpin, Denis ^{[1
]}

Bourdin, Arnaud ^{[2
]}

Chanez, Pascal ^{[1
]}

机构：

[1] Univ Aix Marseille 1, AP HM Inserm CNRS, Resp Dept, U 1067 UMR7333, Marseille, France

[2] Arnaud Villeneuve Hosp, Resp Dept, Montpellier, France

来源：

THERAPEUTIC ADVANCES IN CHRONIC DISEASE | 2014年 / 5卷 / 02期

关键词：

aclidinium bromide; asthma; chronic obstructive pulmonary disease; glycopyrronium bromide; long-acting muscarinic receptor antagonists; tiotropium bromide;

D O I：

10.1177/2040622313518227

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Acetylcholine (neuronal and non-neuronal origin) regulates bronchoconstriction, and mucus secretion. It has an inflammatory effect by inducing attraction, survival and cytokine release from inflammatory cells. Muscarinic receptors throughout the bronchial tree are mainly restricted to muscarinic M1, M2 and M3 receptors. Three long- acting muscarinic receptor antagonists (LAMAs) were approved for the treatment of chronic obstructive pulmonary disease (COPD) in Europe: once-daily tiotropium bromide; once-daily glycopyrronium bromide; and twice-daily aclidinium bromide. All have higher selectivity for M3 receptors than for M2 receptors, and dissociate more slowly from the M3 receptors than they do from the M2 receptors. Some LAMAs showed anti-inflammatory effects [inhibition of neutrophil chemotactic activity and migration of alveolar neutrophils, decrease of several cytokines in the bronchoalveolar lavage (BAL) including interleukin (IL)-6, tumor necrosis factor (TNF)-a and leukotriene (LT)B4] and antiremodeling effects (inhibition of mucus gland hypertrophy and decrease in MUC5AC-positive goblet cell number, decrease in MUC5AC overexpression). In the clinic, LAMAs showed a significant improvement of forced expiratory volume in 1 second (FEV1), quality of life, dyspnea and reduced the number of exacerbations in COPD and more recently in asthma. This review will focus on the three LAMAs approved in Europe in the treatment of chronic airway diseases.

引用

页码：85 / 98

页数：14

共 83 条

[1] Airway smooth muscle dynamics:: a common pathway of airway obstruction in asthma [J].

An, S. S. ;

Bai, T. R. ;

Bates, J. H. T. ;

Black, J. L. ;

Brown, R. H. ;

Brusasco, V. ;

Chitano, P. ;

Deng, L. ;

Dowell, M. ;

Eidelman, D. H. ;

Fabry, B. ;

Fairbank, N. J. ;

Ford, L. E. ;

Fredberg, J. J. ;

Gerthoffer, W. T. ;

Gilbert, S. H. ;

Gosens, R. ;

Gunst, S. J. ;

Halayko, A. J. ;

Ingram, R. H. ;

Irvin, C. G. ;

James, A. L. ;

Janssen, L. J. ;

King, G. G. ;

Knight, D. A. ;

Lauzon, A. M. ;

Lakser, O. J. ;

Ludwig, M. S. ;

Lutchen, K. R. ;

Maksym, G. N. ;

Martin, J. G. ;

Mauad, T. ;

McParland, B. E. ;

Mijailovich, S. M. ;

Mitchell, H. W. ;

Mitchell, R. W. ;

Mitzner, W. ;

Murphy, T. M. ;

Pare, P. D. ;

Pellegrino, R. ;

Sanderson, M. J. ;

Schellenberg, R. R. ;

Seow, C. Y. ;

Silveira, P. S. P. ;

Smith, P. G. ;

Solway, J. ;

Stephens, N. L. ;

Sterk, P. J. ;

Stewart, A. G. ;

Tang, D. D. .

EUROPEAN RESPIRATORY JOURNAL, 2007, 29 (05) :834-860

[2] Inhibition of neutrophil elastase-induced goblet cell metaplasia by tiotropium in mice [J].

Arai, N. ;

Kondo, M. ;

Izumo, T. ;

Tamaoki, J. ;

Nagai, A. .

EUROPEAN RESPIRATORY JOURNAL, 2010, 35 (05) :1164-1171

[3]

Asano Kazuhito, 2010, Int J Chron Obstruct Pulmon Dis, V5, P277

[4]

Asano Kazuhito, 2008, Int J Chron Obstruct Pulmon Dis, V3, P781

[5] Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma [J].

Bateman, Eric D. ;

Kornmann, Oliver ;

Schmidt, Peter ;

Pivovarova, Anna ;

Engel, Michael ;

Fabbri, Leonardo M. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 128 (02) :315-322

[6]

Belmonte KE, 2005, P AM THORAC SOC, V2, P311

[7]

Belmonte Kristen E, 2005, Proc Am Thorac Soc, V2, P297, DOI 10.1513/pats.200504-043SR

[8] Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison [J].

Bos, I. S. T. ;

Gosens, R. ;

Zuidhof, A. B. ;

Schaafsma, D. ;

Halayko, A. J. ;

Meurs, H. ;

Zaagsma, J. .

EUROPEAN RESPIRATORY JOURNAL, 2007, 30 (04) :653-661

[9] Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD [J].

Brusasco, V ;

Hodder, R ;

Miravitlles, M ;

Korducki, L ;

Towse, L ;

Kesten, S .

THORAX, 2003, 58 (05) :399-404

[10] Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro [J].

Buehling, Frank ;

Lieder, Nadine ;

Kuehlmann, Ulrike C. ;

Waldburg, Nadine ;

Welte, Tobias .

RESPIRATORY MEDICINE, 2007, 101 (11) :2386-2394

← 1 2 3 4 5 6 7 8 9 →